Short-term Impact of Cyplexinol® on Self-reported Joint Pain

ClinicalTrials.gov ID: NCT04764110

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT04764110. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 15, 2026, 5:44 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Short-term Impact of Cyplexinol® on Inflammatory Status and Related Measures in Men and Women With Self-reported Joint Pain

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

In this study, the impact of 900 mg Cyplexinol® taken daily on joint pain over a period of 15 days in comparison with a placebo will be determined using a cross-over double blind design with a 13 day wash out period. In addition, we will measure cytokine production and related variables during the two hour after subjects ingest a single dosage of Cyplexinol® or placebo on days 1 and 15.

Study identification

NCT ID: NCT04764110
Recruitment status: Completed
Study type: Interventional
Phase: Not applicable
Lead sponsor: University of Memphis; Other
Enrollment: 18 participants

Conditions and interventions

Conditions

Joint Pain

Interventions

Cyplexinol Dietary Supplement
Placebo Other

Dietary Supplement · Other

Eligibility (public fields only)

Age range: 30 Years to 65 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Mar 17, 2021 (Actual)
Primary completion: Jan 28, 2022 (Actual)
Completion: Jan 28, 2022 (Actual)
Last update posted: Aug 22, 2022

2021 – 2022

United States locations

U.S. sites: 1
U.S. states: 1
U.S. cities: 1

Facility	City	State	ZIP	Site status
Center for Nutraceutical and Dietary Supplement Reseach	Memphis	Tennessee	38152	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT04764110, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Aug 22, 2022 · Synced Nov 15, 2026